City Therapeutics vs SpyGlass Pharma stock comparison
Score, categories, valuation, dividend, crash risk and price performance of City Therapeutics and SpyGlass Pharma side by side. Figures from the overnight run, closing prices from 19 Nov 2026.
Key figures compared
| CTYCity Therapeutics | SGPSpyGlass Pharma | |
|---|---|---|
| MEQIRI Score | ||
| Score | 58 | 45 |
| Fundamentals | 91 | 10 |
| Growth | 33 | 50 |
| Profitability | 82 | 12 |
| Valuation | no data | no data |
| Technical analysis | 39 | 62 |
| Momentum | 19 | 93 |
| Stability | 62 | 72 |
| Capital allocation | 64 | 41 |
| Price and valuation | ||
| Closing price | $18.35 | $30.78 |
| Market cap | $979.67M | $1.03B |
| P/E | no data | Loss |
| Forward P/E | no data | Loss expected |
| Fair value | no data | no data |
| Fair value versus price | no data | no data |
| Growth and dividend | ||
| Revenue growth per year | −1.6% | no data |
| Dividend yield | 0.0% | 0.0% |
| Risk and performance | ||
| Crash risk | no data | no data |
| Price 1 year | no data | no data |
| Price 5 years | no data | no data |
| Industry | Biotechnology | Biotechnology |
Score and figures from the overnight run, closing prices from 19 Nov 2026. Amounts in US dollars, converted at the ECB rate. Price performance without dividends. The comparison shows figures and is not a recommendation to buy.
Price performance
- City Therapeutics
- SpyGlass Pharma
All lines start at 100 on 15 October 2026, the first trading day of the youngest stock. Closing prices without dividends, each stock in its trading currency.
Questions and Answers
How do City Therapeutics and SpyGlass Pharma compare on the MEQIRI Score?
The MEQIRI Score (0 to 100) is 58 for City Therapeutics and 45 for SpyGlass Pharma. The category Fundamentals differs most, with 91 for City Therapeutics and 10 for SpyGlass Pharma. The score combines eight categories and is recalculated every night.
What is the P/E ratio of City Therapeutics and SpyGlass Pharma?
City Therapeutics: P/E no data, forward P/E no data. SpyGlass Pharma: P/E Loss, forward P/E Loss expected. As of the close on 19 Nov 2026.
What is the dividend yield of City Therapeutics and SpyGlass Pharma?
City Therapeutics: 0.0%. SpyGlass Pharma: 0.0%. Based on payments over the last twelve months.
What is the crash risk of City Therapeutics and SpyGlass Pharma?
City Therapeutics: no data. SpyGlass Pharma: no data. Crash risk means a fall of 30% or more within a year, measured in the backtest against companies of similar size.
Why does the price chart start at 100?
All lines start at 100 on the same day. That shows performance regardless of a stock's price: 150 means 50% more than at the start, 80 means 20% less.
Does the comparison tell me which stock to buy?
No. MEQIRI shows figures and explains them, but gives no buy recommendation and no price target. The score helps you see strengths and weaknesses faster.
